Free Trial
NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

Atea Pharmaceuticals logo
$2.98 -0.01 (-0.33%)
Closing price 04:00 PM Eastern
Extended Trading
$2.98 0.00 (0.00%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Atea Pharmaceuticals Stock (NASDAQ:AVIR)

Key Stats

Today's Range
$2.95
$3.08
50-Day Range
$2.65
$3.22
52-Week Range
$2.60
$4.15
Volume
551,035 shs
Average Volume
298,459 shs
Market Capitalization
$254.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Moderate Buy

Company Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

AVIR MarketRank™: 

Atea Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 507th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Atea Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Atea Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Atea Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Atea Pharmaceuticals is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Atea Pharmaceuticals is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Atea Pharmaceuticals has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Atea Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    4.42% of the float of Atea Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Atea Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Atea Pharmaceuticals has recently decreased by 1.33%, indicating that investor sentiment is improving.
  • Dividend Yield

    Atea Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Atea Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.42% of the float of Atea Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Atea Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Atea Pharmaceuticals has recently decreased by 1.33%, indicating that investor sentiment is improving.
  • News Sentiment

    Atea Pharmaceuticals has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Atea Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for AVIR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.80% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Atea Pharmaceuticals' insider trading history.
Receive AVIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVIR Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Morgan Stanley Remains a Hold on Atea Pharmaceuticals (AVIR)
See More Headlines

AVIR Stock Analysis - Frequently Asked Questions

Atea Pharmaceuticals' stock was trading at $3.35 on January 1st, 2025. Since then, AVIR shares have decreased by 11.0% and is now trading at $2.98.
View the best growth stocks for 2025 here
.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) released its earnings results on Thursday, March, 6th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05.
Read the conference call transcript
.

Atea Pharmaceuticals (AVIR) raised $253 million in an initial public offering on Friday, October 30th 2020. The company issued 11,000,000 shares at a price of $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair served as the underwriters for the IPO.

Top institutional investors of Atea Pharmaceuticals include Peapod Lane Capital LLC (0.53%), Bank of New York Mellon Corp (0.24%) and Rhumbline Advisers (0.14%). Insiders that own company stock include Jean-Pierre Sommadossi, Andrea Corcoran, Bruce Polsky and Wayne Foster.
View institutional ownership trends
.

Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atea Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), PayPal (PYPL) and Broadcom (AVGO).

Company Calendar

Last Earnings
3/06/2025
Today
5/02/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVIR
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+101.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-135,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$6.65 per share
Price / Book
0.45

Miscellaneous

Free Float
69,429,000
Market Cap
$254.86 million
Optionable
Optionable
Beta
0.17
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:AVIR) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners